In Brief D'Amico, Antonucci, and colleagues identify a non-canonical Hedgehogdependent pathway that controls polyamine metabolism. The pathway involves the energy sensor AMPK and the translational regulator CNBP and is essential for Hh-dependent proliferation of medulloblastoma cells. The authors show that targeting this pathway efficiently restrains tumor growth.
INTRODUCTION
The Sonic Hedgehog (Shh) pathway is a critical regulator of embryonic patterning and post-natal stem or progenitor cells (Northcott et al., 2012a) . In the cerebellum, Shh promotes the post-natal mitotic expansion of cerebellar granule progenitors (GCPs) (Wechsler-Reya and Scott, 1999) and the aberrant activation of the signaling in these cells is a leading cause of medulloblastoma (MB) Yang et al., 2008) , the most frequent brain malignancy of the childhood.
Shh ligand binds to the membrane inhibitory receptor Patched (Ptch), thus alleviating its inhibitory activity upon the transmembrane transducer Smoothened (Smo). These events occur at the primary cilium and trigger a cascade of intracellular processes that involve the dynamic association between the Gli transcription factors (Gli1, Gli2, and Gli3) and Sufu, which in turn regulates their activity, processing, and cellular localization (Ryan and Chiang, 2012) .
The aberrant activation of Shh pathway observed in MB can been attributed to mutations or amplifications of genes encoding pathway components, such as Ptch, Smo, Sufu, and Gli2 or other mechanisms (Schroeder and Gururangan, 2014) .
Different small molecule inhibitors of the Shh signaling have been generated and tested, thus providing hope to MB patients. However, the majority of these compounds inhibits Smo activity and is thus inactive in case of mutations occurring at the downstream level. Additionally, trials in patients and animals with tumors driven by mutations of Ptch or Smo have shown that, despite a good initial response, they quickly develop resistance. For these reasons, it is now believed that alternative approaches, preferably targeting downstream components of the signaling, are required (Di Magno et al., 2015) .
Polyamines are small intracellular polycations that control key aspects of cell biology, such as cell replication, translation, cell growth, differentiation, and survival and can be found upregulated in cancer (Casero and Marton, 2007) . The metabolism of polyamines starts from the decarboxylation of ornithine to putrescine, a rate-limiting step catalyzed by ornithine decarboxylase (ODC), the crucial gatekeeper of polyamine metabolism. Putrescine is converted to spermine, which is in turn transformed to spermidine (Tavladoraki et al., 2012) .
Given their critical role, the intracellular concentration of polyamines is kept under tight control by various mechanisms affecting their biosynthesis, catabolism, and transport. The conversion of ornithine to putrescine represents the most critical regulated step. Indeed, the intracellular levels of ODC are promptly adjusted to the cellular needs thanks to different mechanisms affecting its protein stability, transcription, and translation (Shantz and Levin, 2007) . Overexpression of ODC and polyamines are found in a number of malignancies and targeting ODC with the irreversible inhibitor difluoromethylornitine (DFMO) is highly efficient in limiting some malignancies, such as lymphomas or neuroblastomas (Nilsson et al., 2005; Rounbehler et al., 2009) .
With the aim of identifying downstream inhibitors of Hh signaling, we have found a mechanism whereby this pathway controls polyamine metabolism via an AMP kinase (AMPK)-dependent control of ODC biosynthesis. This mechanism involves the small zinc finger protein CNBP, which promotes translation of ODC, in association with the cytoplasmic Hedgehog (Hh) transducer Sufu. Finally, we show that CNBP and polyamine metabolism are necessary for Hh-dependent growth and that their inhibition can be exploited for treatment of Hh-dependent MB.
RESULTS

Hh-Dependent Proliferation Is Accompanied by an Increase of Polyamine Biosynthesis and Is Inhibited by DFMO
To determine whether Hh activation is associated with changes in polyamine metabolism, we studied cerebellar granule cell progenitors (GCPs), the cells of origin of Hh-dependent MB . Exposure of GCPs to Shh induced a significant elevation of the three polyamines, putrescine, spermine, and spermidine, accompanied to a robust increase of cell proliferation (Figures 1A and 1B) . The ODC inhibitor DFMO counteracted the increase of proliferation ( Figure 1B ), thus indicating that polyamine biosynthesis is required for GCPs proliferation. The anti-proliferative effect of DFMO could not be attributed to an inhibition of canonical Hh-dependent transcription, as the mRNA levels of the Hh targets Gli1 and Ptch were not changed by this drug ( Figure S1A ). To investigate if the Hh-induced elevation of polyamines was caused by upregulation of ODC, we measured its mRNAs and protein levels. Interestingly, ODC protein content was increased after treatment of GCPs with Shh, while ODC mRNA levels were unchanged, indicating an Hh mediated post-transcriptional regulation of ODC ( Figures 1C and S1B ). The increase of ODC protein and polyamine levels was also observed in mouse embryonic fibroblasts (MEFs) treated with the Smo agonist SAG ( Figures S1C and S1D ). To understand at what level of the Hh transduction pathway this regulation occurs, we used MEF cells deleted of genes encoding two key Hh inhibitors: Ptch and the cytoplasmic transducer Sufu (Svä rd et al., 2006) . Surprisingly, while DFMO significantly inhibited Ptch À/À MEF proliferation ( Figure 1D , left), this drug failed to inhibit Sufu À/À cell growth ( Figure 1D , right). Consistently, addition of putrescine, the downstream metabolite derived from the ODC-dependent decarboxylation of ornithine, increased the proliferation rate only in Sufu À/À cells, further indicating that the absence of Sufu impairs this metabolic step. Supporting this finding, we observed that the protein levels of ODC (Figures 1E, bottom and S1E) and of the three polyamines ( Figure 1F ) were significantly higher in Ptch À/À than in Sufu À/À cells, while ODC mRNA levels were not different in the two cell lines (Figure 1E, top) . Gli1 protein levels were also comparable in both cell lines, indicating a similar degree of activation of the Hhdependent transcriptional output ( Figure 1E ). Knock down of ODC in Ptch À/À MEF cells caused a significant decrease of cell proliferation and polyamine content ( Figure S1F ), confirming the importance of this enzyme for cell proliferation in this context. Therefore, these data indicate that ODC protein is upregulated via a Sufu-mediated mechanism acting at post-transcriptional level. Since Sufu did not affect ODC stability ( Figure S1G ), this suggests that Sufu regulates ODC biosynthesis, likely affecting the function of some unknown modulator.
Sufu Binds and Stabilizes CNBP to Regulate ODC Translation To shed light on this, we expressed FLAG-tagged Sufu in HEK293 cells and performed mass spectrometry analysis on FLAG immunoaffinity purified Sufu-bound proteins. Among the hits with the highest coverage (Table S1 ), we found CCHC type Nucleic acid Binding Protein (CNBP), a zinc finger protein that binds single stranded RNA and DNA and functions as a nucleic acid chaperone (Calcaterra et al., 2010) . Notably, CNBP was shown to regulate ODC translation through an internal ribosome entry site (IRES)-mediated mechanism (Sammons et al., 2010) . We generated and validated a CNBP antibody ( Figure S2A ) and confirmed the ability of CNBP to bind Sufu at an endogenous level and in vitro (Figures 2A and S2B ). We also ruled out the involvement of CNBP in the Sufu-mediated regulation of Gli transcriptional activity, stability, and processing and any competition with the Gli/Sufu complex ( Figures S2C-S2F ).
Knock down of CNBP with different shRNAs caused a reduction of ODC protein levels ( Figure 2B , middle). To confirm that this reduction was related to the ability of CNBP to regulate ODC IRES-dependent translation, we used the bicistronic ODC-Luc vector (Sammons et al., 2010) (Figure 2B, bottom) . This construct contains: (1) the renilla CDS, (2) the luciferase CDS, and (3) the intercistronic ODC 5 0 UTR. This cassette is expressed as a single transcript, under the control of the CMV promoter. Translation of the renilla gene (the most 5 0 of the two open reading frames, ORFs) is cap-dependent and terminates with the TAA stop codon. Translation of the luciferase gene occurs through the ODC internal initiation site (IRES), located in the intercistronic region. Therefore, the luciferase values represent the ODC IRES activity of the intercistronic region and are normalized for the constitutive renilla activity (Sammons et al., 2010) . Knock down of CNBP reduced the luciferase, but not the renilla activity, confirming the ability of this protein to regulate ODC IRES-dependent translation (Figure 2B, top) .
Northern blot analysis of RNA extracted from control or CNBPdeficient cells transfected with ODC-Luc did not show the presence of accessory bands, demonstrating that the effect of CNBP was not related to RNA splicing processes ( Figure S2G ) of the bicistronic transcript.
To rule out potential plasmid artifacts and to verify that this effect was a genuine IRES-dependent process, we transfected NIH 3T3 cells with in vitro transcribed, monocistronic IRES ODCLuciferase mRNA, conjugated to the non-physiological cap analog ApppG, and containing a stable stem loop structure at the 5 0 end to inhibit scanning (Gilbert et al., 2007) A) Polyamine levels in P7 GCPs treated with Shh or BSA as control for 48 hr (*p < 0.01 Shh versus BSA). The polyamine content was measured by GC-MS and normalized to the protein concentration in the extracts (nmol/mg protein). The results are expressed as fold change, relative to untreated cells for each polyamine and represent the average ± SD of three independent experiments, each performed in triplicate (putrescine, Put; spermine, Spm; and spermidine, Spd). (B) BrdU incorporation assay on GCPs treated with DFMO (5 mM) for 72 hr and with Shh or BSA as control for the last 48 hr (*p < 0.01 Shh versus BSA and **p < 0.05 Shh DFMO versus Shh NT). The results are shown as the average ± SD of three independent experiments, each performed in triplicate. (C) ODC mRNA levels normalized by GAPDH levels (top) and ODC protein levels (bottom) in P7 GCPs treated with Shh or BSA as control for 24 hr; actin, loading control. The results are shown as the average ± SD of three independent experiments, each performed in triplicate. Figure S1 . Figure 2C, right) . This confirmed the presence of genuine IRES activity in the ODC 5 0 UTR (Pyronnet et al., 2000) . CNBP depletion significantly reduced this IRES-dependent activity ( Figure 2D , left), whereas exogenous CNBP induced translation of ApppG +IRES mRNA, but did not change the translational activity of control ÀIRES ( Figure 2D , right). Thus, CNBP is a bona fide regulator of ODC IRES-dependent translation.
Ablation of CNBP decreased polyamines levels ( Figure 2E , left) and the proliferation rate of MEF Ptch À/À cells, and this effect was rescued by addition of putrescine ( Figure 2E , right), supporting that loss of CNBP impairs the same metabolic step of Sufu.
To determine whether Sufu and CNBP are both associated with translational complexes, we performed polysomal fractionation. As shown in Figures 2F and S2H, CNBP and Sufu copurified in the polyribosomes fractions and EDTA treatment, which displaces the binding between the ribosomal subunits, disrupted this association, demonstrating that both proteins are associated with actively translating complexes. CNBP and Sufu were also bound to ODC mRNA, as revealed by RNA-IP ( Figure 2G ), further indicating their involvement in ODC translation. Consistently, the absence of Sufu caused a reduction of ODC-Luc activity ( Figure 2H ), indicating that Sufu is involved in the regulation of ODC translation. Interestingly, we observed a reduction of CNBP protein, but not mRNA levels, in Sufu-deficient cells (Figure 2I, bottom) , suggesting that Sufu regulates CNBP at posttranscriptional level.
Based on previous data illustrating the ability of Sufu to bind and stabilize Gli proteins Humke et al., 2010; Wang et al., 2010) , we hypothesized that Sufu could play a similar role in this context, by preventing CNBP degradation. Toward this end, we incubated wild-type (WT) and Sufu À/À cells with the protein synthesis inhibitor cycloheximide (CHX) for different time points and observed that CNBP half-life was significantly shorter in Sufu-deficient cells ( Figure 3A ). The specific involvement of Sufu was demonstrated by its retroviral-mediated reconstitution in Sufu À/À cells, which restored CNBP levels (Figure 3B) . Incubation of Sufu À/À cells with the proteasome inhibitor MG132 rescued the expression of CNBP and of Gli3, used as control , indicating the involvement of proteasomal degradation in this process ( Figure 3C ). In agreement with this observation, we found that both ectopic and endogenous CNBP were efficiently polyubiquitinated, a process that was increased by Sufu knockdown and decreased by its overexpression ( Figures 3D, 3E , S3A, and S3B). Thus, Sufu binds CNBP and prevents its ubiquitination and proteosomal degradation, thereby increasing its stability.
Hh Activation Increases ODC Biosynthesis via AMPK/CNBP
Since we observed increased expression of ODC protein and polyamine biosynthesis in Hh-activated cells ( Figures 1A, 1C , and S1B-S1D), we next wondered whether and how activation of Hh pathway perturbs this Sufu/CNBP-mediated mechanism.
In co-immunoprecipitation studies with equal amounts of CNBP, we observed that upon exposure of cells to SAG, the binding to endogenous Sufu was promptly increased (Figures 4A and S4A) , leading to accumulation of CNBP protein (Figures 4B and S4B) . Similarly, CNBP levels were higher in Ptch À/À cells, compared to control cells and in GCPs treated with Shh peptide ( Figures 4C and S4C ).
To determine whether this upregulation is associated with an increased translational activity of CNBP, we performed polysomal fractionation analysis in control and Hh-activated cells.
Following SAG activation, CNBP was loaded on polysomal fractions and EDTA treatment disrupted this association ( Figures  4D, S4D , and S4E). Consistently, treatment with SAG increased the recruitment of CNBP to ODC 5 0 UTR in RNA-IP experiments ( Figure 4E ). Paralleling CNBP, ODC protein levels were upregulated in Ptch À/À MEF cells, compared to WT MEF cells, and knock down of CNBP abolished this effect ( Figure 4F ). The increase of ODC protein was not dependent on differences in mRNA synthesis and/or stabilization, since ODC mRNA levels were unchanged ( Figure S4F ), neither could be attributed to variations of protein stability, as there were no differences in ODC degradation rate between WT and Ptch À/À cells ( Figure S4G ).
The addition of the protein synthesis inhibitor CHX prevented the Hh-induced upregulation of ODC ( Figure S4H ), thus indicating that the increase was dependent on translation. To directly demonstrate an increase in ODC protein synthesis, we performed in vivo metabolic [
S]-methionine labeling followed by ODC immunoprecipitation (IP). Compared to WT cells, Ptch
À/À cells showed a significant increase of metabolically labeled, newly synthesized ODC protein in the presence of the proteasome inhibitor MG132 ( Figures 4G and S4I ). Consistently, treatment of cells with SAG strongly increased the ODC-Luc IRES-dependent activity, and this effect was disrupted by CNBP knockdown ( Figure 4H ). Therefore, Hh induces ODC translation through CNBP. We next sought to understand the signaling pathway connecting Smo to CNBP. Toward this end, we analyzed the CNBP sequence to identify putative residues that could be subjected to post-translational modifications. We noticed a potential AMPK-consensus site (LARECTIEAT), evolutionary conserved ( Figure 5A ), located in the C-terminal region that diverged from the optimal AMPK site for having the T in position +4 instead of a hydrophobic residue. A similar variation was previously identified in one of the AMPK sites of FOXO3 (Greer et al., 2007) . S5D ) and to KAAD cyclopamine (Figures 5F, S5E, and S5F), which binds Smo and acts as an inhibitor of the canonical pathway, but as a partial agonist of the non-canonical branch (Teperino et al., 2012) . To determine if cyclopamine activates the non-canonical branch also in tumor cells driven by constitutive Hh activation, we tested its effect in primary MB cells generated in conditional Math1-Cre/Ptc C/C mice (Yang et al., 2008) . We will refer to these cells as ''primary MB cells'' within text and figures. Exposure of these cells to cyclopamine did not induce AMPK activation and polyamine production, while it robustly inhibited the expression of the Hh target gene Gli1 ( Figure S5G ). Consistent with previous observations (Teperino et al., 2012) , activation of this non-canonical mechanism is dependent on the integrity of the primary cilium, since SAG failed to induce CNBP, AMPK phosphorylation, and putrescine content in cilia-deficient Itf88 À/À MEF cells ( Figure S5H ).
Thus, activation of the non-canonical Hh-AMPK pathway promotes upregulation of ODC and polyamines in normal cells, but not in tumors sustained by loss of Ptch1.
To determine if CNBP is phosphorylated by AMPK at the putative threonine 173, we performed in vitro kinase assay with recombinant CNBP or its T173A mutant. WT CNBP efficiently incorporated 32 P in the presence of AMPK, whereas the T173A mutant did not ( Figure 5G ), thus demonstrating that AMPK phosphorylates CNBP only at this residue. We then immunoprecipitated ectopically expressed CNBP from WT and AMPK À/À cells and performed western blotting with an antibody recognizing AMPK-phosphorylated substrates. CNBP was phosphorylated in WT, but not AMPK À/À cells ( Figure 5H ). Activation of Hh with SAG increased the AMPK-mediated phosphorylation of both endogenous and ectopic CNBP ( Figures 5I and 5J ), and this modification was completely abrogated by mutation of the T173 residue to alanine ( Figure 5J ). To study the activity of the T173A mutant and to rule out the possibility of overexpression artifacts, we knocked down endogenous CNBP with shRNA (D) Polysomal recruitment of CNBP in SAG-treated NIH 3T3 cells. The cells were grown in low serum (0.5% BS) medium overnight to allow full Hh response and then treated with either DMSO or SAG for 4 hr. The cells were lysed and loaded onto a 15%-50% sucrose gradient in the presence or absence of EDTA, as described in Figure 2D . The CNBP protein levels in each fraction were analyzed by western blotting.
(E) RNA-IP of ODC mRNA. The NIH 3T3 cells, treated with SAG or DMSO for 4 hr, were crosslinked and lysed. The lysates were immunoprecipitated with CNBP or control IgG antisera. The eluted ODC mRNAs were analyzed as in Figure 2E 
(legend continued on next page)
targeting the 3 0 UTR region and reintroduced WT and T173A CNBP ( Figure S5I ). Reconstitution of CNBP-deficient cells with CNBP WT rescued ODC-Luc activity and putrescine levels, whereas the T173A mutant had a significantly reduced activity ( Figures 5K and S5I) .
The CNBP T173A mutant was no longer upregulated by SAG ( Figure S5J ) and showed a significantly reduced half-life compared to the WT protein ( Figure S5K ).
Since the stability of CNBP depends on its association with Sufu, we tested the binding of Sufu to CNBP WT, T173A, and the phosphomimetic T173D mutant. Compared to WT CNBP, the T173A mutant bound Sufu with reduced affinity, while the T173D showed an increased affinity ( Figures 5L and S5L ), indicating that phosphorylation of T173 favors the formation of the complex.
In keeping with this finding, the phosphomimetic T173D mutant promoted significantly higher ODC-Luc activity and polyamines production ( Figure S5M ).
Collectively, these data indicate that T173 phosphorylation represents the critical regulated checkpoint of this Hh/AMPKmediated regulation of CNBP.
ODC and CNBP Are Elevated in MB, and their Targeting Prevents MB Growth
To explore the pathophysiological relevance of this mechanism, we analyzed CNBP and ODC levels in Hh-dependent MB developed in conditional Math1-Cre/Ptc C/C mice, where Hh signaling is constitutively hyperactive ( Figure S6A ). Compared to a normal adult cerebellum, CNBP, ODC, Sufu, and phosphorylated AMPK were elevated in MB samples ( Figures 6A and S6B) , and this was accompanied by a strong upregulation of the three polyamines ( Figure 6B ).
We next analyzed CNBP and ODC expression in a cohort of 42 human MBs, divided according to the molecular subgroup (five wingless, WNT; seventeen SHH; ten group 3; and ten group 4) as previously described (Mastronuzzi et al., 2014; Miele et al., 2015) .
CNBP and ODC staining were strongly increased in the SHH molecular subgroup compared to a normal adult cerebellum, which showed a negative staining for ODC and a weak positivity for CNBP. A positive staining of CNBP and ODC was also observed in the group 3, while the WNT and group 4 molecular subgroups displayed a weaker staining ( Figure 6C ). Negative controls were also performed ( Figure S6C ).
We next analyzed the cohort of seventeen human SHH MBs belonging to the three histological subgroups: desmoplastic, classic, and large cell anaplastic (LCA) (Kool et al., 2012; Northcott et al., 2012b) . The staining for both CNBP and ODC was strongly positive in all the MB analyzed independently of their histological classification ( Figure 6D ).
The strong increase of CNBP, ODC, and polyamine levels in Hh-dependent tumors prompted us to evaluate the consequence of turning off this mechanism in tumor cells.
We first tested different shRNA expressing lentiviruses targeting CNBP for their efficacy in knocking down CNBP and consequent ODC downregulation in primary SHH MB ( Figure 7A) . We selected the shRNA #58 and used it in all the subsequent experiments.
Ablation of CNBP caused a significant reduction of polyamine content ( Figure 7B ) and cell proliferation in primary SHH MB cells and in Shh-treated GCPs, as assessed by BrdU incorporation assays ( Figures 7B, 7C, and S7A) .
Exposure of primary SHH MB cells to DFMO resulted in a robust inhibition of tumor cell proliferation ( Figure 7D ), without affecting Gli1 mRNA levels ( Figure S7B ). Accordingly, the levels of the three polyamines putrescine, spermine, and spermidine in MB cells were downregulated by this drug ( Figure 7E ).
To determine whether DFMO could inhibit proliferation of tumors sustained by upregulation of Gli, independently of upstream activation of Smo, we used the TC-71 tumor cells. Gli1 drives the proliferation of these cells as a consequence of downstream events causing its aberrant transcription (Beauchamp et al., 2009 (Beauchamp et al., , 2011 . Indeed, the direct Gli1 inhibitor ATO strongly inhibits proliferation of these cells, while they do not respond to the treatment with cyclopamine (Beauchamp et al., 2011) .
Compared to the Ptch À/À MEF cells, TC-71 cells showed comparable levels of Gli1 ( Figure 7F ). Treatment of these cells with DFMO did not affect their proliferation, while ATO had a strong inhibitory effect ( Figure 7G ). Knock down of Gli1 caused a significant decrease of their proliferation, without affecting polyamine levels ( Figure 7H ). Thus, Gli1-driven proliferation does not require changes of polyamine content.
To study the effect of targeting the CNBP/ODC axis in vivo, we allografted tumor cells explanted from Ptch À/À MB and stably transduced with shCNBP or control lentiviruses into nude mice. When the tumor reached the volume of 100 mm 3 , half of the mice from each group were treated with 0.5% DFMO in the drinking water until the end of the experiment, monitoring the growth of the tumor every other day. As shown in Figures 7I,  7J , and 7K, MB growth and polyamine content were strongly reduced in CNBP-deficient tumors, compared to controls. Inhibition of ODC with DFMO also had a similar inhibitory effect on tumor growth and polyamine content. Notably, DFMO did not cause a further decrease of the growth and polyamine levels, neither a reduction of Gli1 mRNA ( Figure S7C depleted of CNBP, demonstrating that this drug requires CNBP to exert its effect. Taken together, these data show that CNBP and ODC are elevated in Hh-dependent MB and that genetic or pharmacological targeting of the Hh-ODC axis is effective in counteracting the growth of MB both in vitro and in vivo.
DISCUSSION
In this work, we have demonstrated the ability of Hh signaling to control a druggable metabolic process, which is required for normal and MB growth.
The non-canonical Smo/AMPK-dependent signaling route was originally identified in adipocytes, muscle cells, and fibroblasts, where it promotes a rapid metabolic rewiring toward glycolysis and increase of glucose uptake (Teperino et al., 2012) . Here, we provide evidence that the same transduction axis is essential to control the proliferation of cerebellar GCPs and their tumor counterpart by regulating ODC, the key gatekeeper of polyamines metabolism.
The levels of ODC are controlled by CNBP, a small conserved protein known to regulate neuronal cell proliferation and forebrain development (Chen et al., 2003) , in response to unknown signals. We show here that following Hh activation, CNBP is phosphorylated at T173 by AMPK and promotes translation of ODC, thereby controlling cell proliferation. Thus, in contrast to the classical mode of action as a tumor suppressing kinase, here AMPK is engaged in a process that supports, rather than counteracts, tumor cell growth. These observations are in line with the emerging view that AMPK may act as tumor suppressor or a contextual oncogene, depending on degree or duration of its activation (Liang and Mills, 2013) . It is likely that Hh signaling activates AMPK to a level where it prevails its tumor promoting effect. Interestingly, we also show a role for AMPK in promoting, rather than inhibiting, a translational process. Indeed, our findings illustrate that, by activating CNBP, AMPK promotes IRES-dependent translation, an emergency mechanism utilized by cells to cope with different adverse conditions, including metabolic, hypoxic, or oncogenic stress (Spriggs et al., 2008) .
In a previous work, it was proposed that in cardiac myoblasts, AMPK limits ODC activity, particularly when cells are exposed to isoproterenol, which was found to phosphorylate AMPK and to increase polyamine content (Passariello et al., 2012) . This suggests a context-dependent role of this kinase in regulating polyamine metabolism, possibly related to its involvement in different intracellular networks.
All these aspects add a further level of complexity to the role of AMPK in cancer and underscore the importance to carefully evaluate the use of AMPK agonists as anti-cancer drugs, taking into account the possibility of the dual effect on tumor growth and stress adaptation.
A similar bifunctional mode of action is observed here with Sufu, which supports ODC translation and polyamine metabolism by increasing the stability of CNBP.
This observation is seemingly paradoxical, since Sufu is generally described as a tumor suppressor, and its monoallelic deletion appears to be sufficient to confer a Hh gain-of-function phenotype in mice (Cooper et al., 2005; Svä rd et al., 2006) . However, MB does not develop in Sufu +/À mice, unless they carry a p53 À/À background (Lee et al., 2007) and conditional cerebellar Sufu À/À mice do not display signs of early MB or pre-tumoral lesions, such as thickening of the external granule layer (Kim et al., 2011; Yang et al., 2008) , typically observed in other Hh gain of function models, such as the cerebellar ptch deletion or smo activating mutations (Wu et al., 2011) . Thus, it is possible that the lack of MB development in Sufu deficient animals may reflect the ability of this protein to mediate both tumor suppressing and promoting functions of Hh signaling, like polyamine biosynthesis.
Mono and biallelic mutations of Sufu have been also found in human MB (Brugiè res et al., 2012; Pugh et al., 2012; Robinson et al., 2012) and are believed to cause activation of the canonical pathway. Whether these mutations also affect the AMPK-dependent route remains to be determined.
In addition to SHH subgroup, CNBP and ODC protein levels are elevated in group 3 MBs. While the mechanism underlying the increase of CNBP has to be established, it is possible that the elevation of ODC could be attributed, at least in part, to overexpression of cMyc, a typical alteration found in this molecular subgroup (DeSouza et al., 2014) . Indeed, ODC is a transcriptional target of cMyc and is typically overexpressed in cMyc-driven malignacies (Bello-Fernandez et al., 1993; Nilsson et al., 2005) .
A key finding of this work is that targeting of this Hh/CNBP/ ODC metabolic axis efficiently prevents the growth of MB cells in vitro and in vivo by reducing intracellular polyamine content. Increased polyamine levels had been observed in MB in an old study (Scalabrino et al., 1982) , but their role and the underlying mechanisms were not known, as well as the existence of different molecular MB subgroups. Here, we demonstrate that a non-canonical, Smo-dependent, and Gli-independent mechanism is responsible for the elevations of the polyamine content observed in SHH MB.
This evidence appears to be relevant since a growing body of evidence is documenting the occurrence of resistance to Smo antagonists in the treatment of MB and other Hh driven tumors. Explanations to this phenomenon have been provided with the occurrence of novel Smo mutations and/or with the identification of oncogenic signaling pathways involving ERK, AKT, and mTOR/S6K1, which promote Smo-independent Gli activation or non-canonical Gli-independent cascades (Di Magno et al., 2015) . These observations all indicate that full inhibition of the Hh pathway requires alternative approaches, inhibiting the signaling at multiple levels rather than targeting the receptor apparatus alone. Interestingly, the canonical Smo antagonists cyclopamine and GDC-0449 appear to function as selective partial agonists of this non-canonical Hh/AMPK branch in metabolic cells (Teperino et al., 2012) and in GCPs. Cyclopamine inhibits canonical Hh signaling and counteracts cell growth only in tumors with constitutive activation of the receptor apparatus (i.e., in Ptch1 loss of function). In these tumors, the activity of Smo is constitutively increased on both canonical and noncanonical branches. In addition, cyclopamine efficiently represses Gli-dependent transcription, but does not result in any further activation of the AMPK-polyamine axis in cultured Ptch À/À SHH-MB cells. Therefore, the effect of cyclopamine differs between normal and tumor cells: in normal cells cyclopamine acts as a partial agonist of the non-canonical Hh signaling, but inhibits the canonical route. In contrast, in Hhdependent tumors, cyclopamine inhibits the canonical pathway, but is unable to induce any further activation of the non-canonical branch.
To address the relevance of the non-canonical AMPK-ODC pathway in SHH MB, we have targeted both CNBP (shRNA) and/or ODC (DFMO) and observed a significant inhibition of the growth of MB cells from conditional Ptch KO mice, where Smo is constitutively activated. Thus, turning off the non-canonical branch limits MB growth, even if the canonical signaling is still hyperactive, indicating that both pathways are required for growth.
Further supporting our findings, a previous report showed that treatment of Ptch +/À mice with DFMO prevented the formation of UV-induced basal cell carcinoma, although the underlying mechanism was not clarified (Tang et al., 2004) . Compared to other chemotherapeutic compounds, DFMO is a well-tolerated drug with a modest toxicity, consisting in thrombocytopaenia, gastrintestinal effects, and reverible hearing loss. Recent clinical trials have demonstrated its significant effect as a chemopreventive agent in tumors like neuroblastoma, skin, and colon cancers (Jeter and Alberts, 2012) . Our preclinical data support the use of DFMO also as a pharmacological agent for MB. Whether this approach, alone, or in combination with other strategies, will be successful in human MB patients, thus, represents a relevant open question raised in this work.
EXPERIMENTAL PROCEDURES Drug Treatments
The ODC inhibitor DFMO (Sigma, 5 mM) and putrescine (Sigma, 10 mM) were added to the medium for the indicated times.
For SAG treatment, NIH 3T3 cells were incubated in low serum (0.5% BS) overnight. MEF WT and Itf88 À/À were incubated in 1% BSA overnight and then exposed to SAG (200 nM, Enzo Life Sciences) or KAAD (0.1 mM, Calbiochem) for the indicated times. MEF Sufu À/À and HEK293T cells were treated with MG132 (50 mM, Sigma) for 6 hr. MEFs cells were treated for the indicated times with 100 mg/ml protein-synthesis inhibitor CHX (Sigma). GCPs were treated with recombinant Shh-N-terminal peptide (R&D Systems, 3 mg/ml in BSA), with KAAD (0.1 mM, Calbiochem), A769662 (25 mM, Santa Cruz Biotechnology), for the indicated times. MEF cells and GCPs were pre-treated with CC (20 mM, Millipore) for 20 min and then stimulated with SAG or Shh, respectively, for the indicated times. For polyamine quantitation, MEF Ptch À/À and GCPs were treated with 10 mM CC for 24 hr (Teperino et al., 2012) . Primary MB cells were treated with KAAD (0.5 mM) for the indicated times. TC-71 cells were treated with 5 mM DFMO (Sigma) or 5 mM arsenic trioxide (ATO, Sigma) for the indicated times. RNA IP Cells were treated, formaldehyde crosslinked, lysed, and sonicated. Lysates were immunuoprecipitated with the specified antibodies and the immunocomplexes washed extensively.
Polyamine Analysis
Eluted mRNAs were analyzed by real-time qRT-PCR.
MB Allograft Models
A parental murine MB model was derived from Math1-Cre/Ptch C/C mice (Yang et al., 2008) . Nude female mice were housed under standard conditions. Briefly, freshly isolated MB were mechanically dissociated into single-cell suspensions in HBSS (GIBCO) supplemented with Pen/Strep. The 5 3 10 6 viable cells were harvested in duplicate and, after 24 hr, infected with control shRNA or shCNBP58 lentiviral particles. After 96 hr, 2 3 10 6 viable cells were suspended in equal volumes of PBS and Matrigel (BD PharMingen) and implanted subcutaneously in both flanks in adult athymic nude mice (Charles River Laboratories). Animals from the two subgroups were randomized and divided in two further subgroups. Treatment was initiated when tumor volume reached 100 mm 3 . Mice (control: n = 5 and shCNBP: n = 5) were treated with 0.5% DFMO in the drinking water or only water (control: n = 5 and shCNBP: n = 5) and tumors sizes were measured every day using a caliper. Volume was calculated as V = (L 3 W 2 )/ 2 (Kim et al., 2013) . Growth patterns were summarized graphically by plotting the mean and SD for each treatment group over time. Study events were recorded and analyzed using GraphPad Prism software (v6.05). CNBP knockdown was confirmed by qPCR in all tumor samples at the end of the experiment.
Statistical Analysis
Statistical analysis was performed using StatView 4.1 software (Abacus Concepts). Results are expressed as mean ± SD from at least three independent experiments, each performed in triplicate. Statistical differences were analyzed with the Mann-Whitney U test for non-parametric values and a p < 0.05 was considered significant.
Full details of the Experimental Procedures and description of standard techniques are provided in Supplemental Information.
The Institutional Review Board approved the studies involving human samples and informed consent was obtained from all subjects.
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